

HR 3497

MODDERN Cures Act of 2011

Congress: 112 (2011–2013, Ended)

Chamber: House

Policy Area: Health

Introduced: Nov 18, 2011

Current Status: Referred to the Subcommittee on Intellectual Property, Competition and the Internet.

Latest Action: Referred to the Subcommittee on Intellectual Property, Competition and the Internet. (Dec 2, 2011)

Official Text: <https://www.congress.gov/bill/112th-congress/house-bill/3497>

Sponsor

Name: Rep. Lance, Leonard [R-NJ-7]

Party: Republican • **State:** NJ • **Chamber:** House

Cosponsors (48 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Inslee, Jay [D-WA-1]	D · WA		Dec 2, 2011
Rep. Latham, Tom [R-IA-4]	R · IA		Dec 2, 2011
Rep. Frank, Barney [D-MA-4]	D · MA		Dec 12, 2011
Rep. Hultgren, Randy [R-IL-14]	R · IL		Dec 12, 2011
Rep. Walsh, Joe [R-IL-8]	R · IL		Dec 12, 2011
Rep. Moran, James P. [D-VA-8]	D · VA		Feb 6, 2012
Rep. Guthrie, Brett [R-KY-2]	R · KY		Feb 14, 2012
Rep. Roskam, Peter J. [R-IL-6]	R · IL		Mar 7, 2012
Rep. Lee, Barbara [D-CA-9]	D · CA		Apr 16, 2012
Rep. Jackson, Jesse L., Jr. [D-IL-2]	D · IL		May 9, 2012
Del. Norton, Eleanor Holmes [D-DC-At Large]	D · DC		May 16, 2012
Rep. Brown, Corrine [D-FL-3]	D · FL		May 16, 2012
Rep. Clay, Wm. Lacy [D-MO-1]	D · MO		May 16, 2012
Rep. Critz, Mark S. [D-PA-12]	D · PA		May 16, 2012
Rep. Jones, Walter B., Jr. [R-NC-3]	R · NC		May 16, 2012
Rep. King, Peter T. [R-NY-3]	R · NY		May 16, 2012
Rep. Neal, Richard E. [D-MA-2]	D · MA		May 16, 2012
Rep. Walden, Greg [R-OR-2]	R · OR		May 16, 2012
Rep. Harper, Gregg [R-MS-3]	R · MS		May 17, 2012
Rep. Luetkemeyer, Blaine [R-MO-9]	R · MO		May 17, 2012
Rep. Crenshaw, Ander [R-FL-4]	R · FL		May 30, 2012
Rep. Filner, Bob [D-CA-51]	D · CA		May 30, 2012
Rep. Lujan, Ben Ray [D-NM-3]	D · NM		May 30, 2012
Rep. Palazzo, Steven M. [R-MS-4]	R · MS		May 30, 2012
Rep. Pascrell, Bill, Jr. [D-NJ-8]	D · NJ		May 30, 2012
Rep. Sessions, Pete [R-TX-32]	R · TX		May 30, 2012
Rep. Tiberi, Patrick J. [R-OH-12]	R · OH		May 30, 2012
Rep. Wolf, Frank R. [R-VA-10]	R · VA		May 30, 2012
Rep. Loeb sack, David [D-IA-2]	D · IA		Jun 8, 2012
Rep. Pence, Mike [R-IN-6]	R · IN		Jun 26, 2012
Rep. Sutton, Betty [D-OH-13]	D · OH		Jun 26, 2012
Rep. Carson, Andre [D-IN-7]	D · IN		Jul 10, 2012
Rep. Paulsen, Erik [R-MN-3]	R · MN		Jul 10, 2012
Rep. Bilbray, Brian P. [R-CA-50]	R · CA		Jul 24, 2012
Rep. Rangel, Charles B. [D-NY-15]	D · NY		Jul 24, 2012
Rep. Ruppersberger, C. A. Dutch [D-MD-2]	D · MD		Jul 24, 2012
Rep. Baca, Joe [D-CA-43]	D · CA		Aug 2, 2012
Rep. Donnelly, Joe [D-IN-2]	D · IN		Aug 2, 2012
Rep. Ellison, Keith [D-MN-5]	D · MN		Aug 2, 2012
Rep. Rokita, Todd [R-IN-4]	R · IN		Aug 2, 2012
Rep. Woolsey, Lynn C. [D-CA-6]	D · CA		Aug 2, 2012

Cosponsor	Party / State	Role	Date Joined
Rep. Schwartz, Allyson Y. [D-PA-13]	D · PA		Sep 10, 2012
Rep. Bucshon, Larry [R-IN-8]	R · IN		Sep 20, 2012
Rep. Dold, Robert J. [R-IL-10]	R · IL		Sep 20, 2012
Rep. McCollum, Betty [D-MN-4]	D · MN		Sep 20, 2012
Rep. Runyan, Jon [R-NJ-3]	R · NJ		Sep 20, 2012
Rep. Burton, Dan [R-IN-5]	R · IN		Sep 21, 2012
Rep. Thompson, Mike [D-CA-1]	D · CA		Nov 29, 2012

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Nov 18, 2011
Judiciary Committee	House	Referred to	Dec 2, 2011
Ways and Means Committee	House	Referred to	Nov 22, 2011

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
112 HR 6446	Related bill	Sep 26, 2012: Referred to the Subcommittee on Health.

Summary (as of Nov 18, 2011)

Modernizing Our Drug & Diagnostics Evaluation and Regulatory Network Cures Act of 2011 or the MODDERN Cures Act of 2011 - Requires the Secretary of Health and Human Services (HHS) to: (1) establish the Advanced Diagnostics Education Council to recommend standard terms and definitions related to innovative diagnostics for use by patients, physicians, health care providers, payers, and policy makers.; and (2) publish a guide regarding such terms and definitions.

Sets forth additional factors for the Secretary to consider in determining the payment amount for new clinical diagnostic laboratory tests under gap filling procedures which are used when no comparable existing test is available.

Extends the exclusivity period for a drug or biological product if the diagnostic test related to such drug has been determined by the Secretary to have been developed by, or with the participation of, the manufacturer or sponsor of the drug or biological product, and use of the diagnostic tests provides for or improves: (1) the identification of a patient population for the drug or biological product; or (2) the determination of the most appropriate treatment option for a patient population with the drug or biological product.

Establishes a dormant therapy designation for drugs or biological products that address unmet medical needs. Gives such a drug or biological product 15 years of data exclusivity under which no drug can be approved by relying on the approval or licensure of the dormant therapy.

Actions Timeline

- **Dec 2, 2011:** Referred to the Subcommittee on Intellectual Property, Competition and the Internet.
- **Nov 22, 2011:** Referred to the Subcommittee on Health.
- **Nov 18, 2011:** Introduced in House
- **Nov 18, 2011:** Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- **Nov 18, 2011:** Referred to the Subcommittee on Health.